Elsevier, European Journal of Cancer, 12(51), p. 1511-1528, 2015
DOI: 10.1016/j.ejca.2015.04.026
Full text: Download
Switch maintenance is an effective strategy in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). Pazopanib is an oral, multi-targeted tyrosine kinase inhibitor (TKI). EORTC 08092 evaluated pazopanib given as maintenance treatment following standard first line platinum-based chemotherapy in patients with advanced NSCLC.